



February 09, 2026

To, Listing Department, BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 Ref: BSE Scrip Code: 544497	To, The National Stock Exchange of India Ltd. The Listing Department Exchange Plaza, Bandra – Kurla Complex, Mumbai – 400051, NSE Scrip Code: AHCL
--	---

Sub: Outcome of Board Meeting held on February 09, 2026, of Anlon Healthcare Limited.

Respected Sir/Madam,

Pursuant to Regulations 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("**LODR Regulations, 2015**"), we hereby submit the Outcome of Board Meeting of the Company held on Monday, February 09, 2026 at the Registered Office of the Company where the following matters *inter alia* have been considered, approved, and taken on record by the Board of Directors:

- i) Standalone Unaudited Financial Results for the quarter and nine months ended on December 31, 2025 and Limited Review Report of Auditor's thereon.
- i) Approved the resignation of Mr. Hitesh Bavajibhai Makwana, Chief Financial Officer (CFO) of ANLON HEALTHCARE LIMITED. The resignation letter attached herewith. Details as per LODR, Regulations, 2015 are annexed herewith as **Annexure-A**.
- ii) Approved the appointment of Mr. Naimish Dilipbhai Bhatt as a Chief Financial Officer (CFO) of ANLON HEALTHCARE LIMITED. Details as per LODR Regulations, 2015 are annexed herewith as **Annexure-B**.
- iii) Approved the appointed of Mr. Kishan Vinodkumar Raja as an Independent Director of ANLON HEALTHCARE LIMITED. Details as per LODR Regulations, 2015 are annexed herewith as **Annexure-C**.
- iv) Approved the resignation of Mr. Shailesh Kantilal Thakkar, Independent Director of ANLON HEALTHCARE LIMITED. The resignation letter attached herewith. Details as per LODR Regulations, 2015 are annexed herewith as **Annexure-D**.

A copy of the Standalone Unaudited Financial Results for the quarter and nine months ended on December 31, 2025 and Limited Review Report of Auditor's thereon is attached herewith.

Disclosure as per regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is attached herewith.

ANLON HEALTHCARE LIMITED

CIN No.: U24230GJ2013PLC077543

REGISTERED OFFICE: 101/102, Silver Coin Complex, Opp. Crystal Mall, Kalawad Road, Rajkot-360005, Gujarat (INDIA)

PHONE NO.: +91-7069690081/82 | Email: info@anlonhealthcare.com | www.anlon.in



Meeting Commenced on 02:00 p.m. IST and Concluded on 03:00 p.m. IST.

You are requested to take the above information on your record.

Thanking You.

For ANLON HEALTHCARE LIMITED

**PUNITKUMAR RASADIA
MANAGING DIRECTOR
DIN: 06696258**

ANLON HEALTHCARE LIMITED

CIN No.: U24230GJ2013PLC077543

REGISTERED OFFICE: 101/102, Silver Coin Complex, Opp. Crystal Mall, Kalawad Road, Rajkot-360005, Gujarat (INDIA)

PHONE NO.: +91-7069690081/82 | Email: info@anlonhealthcare.com | www.anlon.in



Annexure A

RESIGNATION OF CHIEF FINANCIAL OFFICER

Details of Resignation of Chief Financial Officer as per Disclosure of Information pursuant to Regulation 30 of SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015 read with Schedule III of SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 09, 2015, as updated from time to time.

Sr. No.	Details of events that needs to be Provided	Information of such event(s)
1.	Reason for change viz. appointment, Resignation, removal, death or otherwise.	Resignation of Mr. Hitesh Bavanjibhai Makwana, Chief Financial Officer of the Company.
2.	Date of Appointment/ Date of Cessation	w.e.f. February 09, 2026
3.	Brief profile (in case of Appointment)	NA
4.	Disclosure of relationship between Directors (in case of appointment of a director)	NA
5.	Letter of resignation along with detailed reasons for resignation	Enclosed as Annexure 1.

ANLON HEALTHCARE LIMITED

CIN No.: U24230GJ2013PLC077543

REGISTERED OFFICE: 101/102, Silver Coin Complex, Opp. Crystal Mall, Kalawad Road, Rajkot-360005, Gujarat (INDIA)

PHONE NO.: +91-7069690081/82 | Email: info@anlonhealthcare.com | www.anlon.in



Annexure B

APPOINTMENT OF CHIEF FINANCIAL OFFICER

Details of Appointment of Chief Financial Officer as per Disclosure of Information pursuant to Regulation 30 of SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015 read with Schedule III of SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 09, 2015, as updated from time to time.

Sr. No.	Details of events that needs to be Provided	Information of such event(s)
1.	Reason for change viz. appointment, Resignation, removal, death or otherwise.	Appointment of Mr. Naimish Dilipbhai Bhatt as a Chief Financial Officer of the Company.
2.	Date of Appointment/ Date of Cessation	w.e.f. February 09, 2026
3.	Brief profile (in case of Appointment)	He has more than 18 years of experience in financial reporting, budgeting, reducing cost, analyzing financial data and compliance management related to accounting and audit. Throughout his career, he has played a significant role in strengthening internal control frameworks and enhancing governance mechanisms by identifying process gaps, implementing control improvements, and ensuring adherence to statutory and audit requirements.
4.	Disclosure of relationship between Directors (in case of appointment of a director)	NA

ANLON HEALTHCARE LIMITED

CIN No.: U24230GJ2013PLC077543

REGISTERED OFFICE: 101/102, Silver Coin Complex, Opp. Crystal Mall, Kalawad Road, Rajkot-360005, Gujarat (INDIA)

PHONE NO.: +91-7069690081/82 | Email: info@anlonhealthcare.com | www.anlon.in



Annexure C

APPOINTMENT OF NON-EXECUTIVE INDEPENDENT DIRECTOR

Disclosure of Information pursuant to Regulation 30 of SEBI (Listing Obligation and Disclosure requirement) Regulations, 2015 read with Schedule III of SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 09, 2015, as updated from time to time.

Sr. No.	Details of events that needs to be Provided	Information of such event(s)
1.	Reason for change viz. appointment, resignation, removal, death or otherwise.	Appointment of Mr. Kishan Vinodkumar Raja (DIN:11522235) as an Additional Non-Executive Independent Director.
2.	Date of Appointment/ Cessation & Terms of appointment	w.e.f. February 09, 2026
3.	Brief profile (in case of Appointment)	<p>Mr. Kishan Vinodkumar Raja is a seasoned Chartered Accountant with over 14 years of post-qualification experience, specializing in Statutory Audit, Corporate Taxation, and Corporate Finance.</p> <p>He is known for his meticulous approach to financial integrity and a deep understanding of the regulatory landscape governing corporate entities.</p> <p>The Company seeks to leverage his extensive experience in risk mitigation and financial oversight during his tenure as an Independent Director, thereby ensuring robust board-level decision-making and enhanced stakeholder protection.</p>
4.	Disclosure of relationship between Directors (in case of appointment of a director)	Director appointed is not related to any other directors of the Company.
5.	Information as required under BSE circular no. LIST/COMP/14/2018-19 and NSE circular no. NSE/CML/2018/24, dated June 20, 2018	Mr. Kishan Vinodkumar Raja is not debarred from holding the office of director by any SEBI order or any other such authority.

ANLON HEALTHCARE LIMITED

CIN No.: U24230GJ2013PLC077543

REGISTERED OFFICE: 101/102, Silver Coin Complex, Opp. Crystal Mall, Kalawad Road, Rajkot-360005, Gujarat (INDIA)

PHONE NO.: +91-7069690081/82 | Email: info@anlonhealthcare.com | www.anlon.in



Annexure D

RESIGNATION OF NON-EXECUTIVE INDEPENDENT DIRECTOR

Disclosure of Information pursuant to Regulation 30 of SEBI (Listing Obligation and Disclosure requirement) Regulations, 2015 read with Schedule III of SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 09, 2015, as updated from time to time.

Sr. No.	Details of events that needs to be Provided	Information of such event(s)
1.	Reason for change viz. appointment, resignation, removal, death or otherwise.	Resignation of Mr. Shailesh Kantilal Thakkar, Independent Director (DIN: 00294480) of the Company. Mr. Shailesh Kantilal Thakkar has resigned from the Company citing his pre-occupation and deteriorating health conditions in the recent past.
2.	Date of Appointment/ Cessation & Terms of appointment	w.e.f. February 09, 2026
3.	Brief profile (in case of Appointment)	Not Applicable
4.	Disclosure of relationship between Directors (in case of appointment of a director)	Not Applicable
5.	Names of other listed entities in which the resigning director holds directorships, indicating the category of directorship and membership of board committees, if any	1. REMEMBER INDIA MEDICOS PRIVATE LIMITED CIN: U24231GJ2004PTC043898
6.	Information as required under BSE circular no. LIST/COMP/14/2018-19 and NSE circular no. NSE/CML/2018/24, dated June 20, 2018	Not Applicable
7.	Letter of resignation along with detailed reasons for resignation	Enclosed as Annexure 2 .
8.	The independent director shall, along with the detailed reasons, also provide a confirmation that there are no other material reasons other than those provided	Mr. Shailesh Kantilal Thakkar has confirmed that there are no material reasons for his resignation other than those mentioned in his resignation letter.

ANLON HEALTHCARE LIMITED

CIN No.: U24230GJ2013PLC077543

REGISTERED OFFICE: 101/102, Silver Coin Complex, Opp. Crystal Mall, Kalawad Road, Rajkot-360005, Gujarat (INDIA)

PHONE NO.: +91-7069690081/82 | Email: info@anlonhealthcare.com | www.anlon.in


Independent Auditor's Review Report on the Quarterly and Year to date Unaudited Standalone Financial Results of the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

**Review Report to
The Board of Directors
Anlon Healthcare Limited**

- (1) We have reviewed the accompanying statement of unaudited standalone financial results of Anlon Healthcare Limited (the 'Company') for the quarter ended December 31, 2025 and year to date from April 01, 2025 to December 31, 2025 (the 'Statement'), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the 'Listing Regulations').
- (2) This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 (Ind AS 34), 'Interim Financial Reporting', prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
- (3) We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we could become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
- (4) Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For, R V D & Co
Chartered Accountants
ICAI Firm Registration No 143936W


Kaushal V. Dave
(Partner)
Membership No 174550
UDIN:26174550FARTIO7275



Date: February 09th, 2026
Place: Rajkot

Antlon Healthcare Limited

CIN: U24230GJ2013PLC077543

Address: 101/102 - Silvercon Complex, Opp. Crystal Mall, Kalawad Road, Rajkot, Gujarat, 360005

Standalone Financial Result for the period ended on 31-12-2025

Rs. in Lakhs

Sr No	Particulars	Quarter Ended		Nine month ended		Year Ended 31 March 2025 Audited
		31-12-2025 Un Audited	30-9-2025 Un Audited	31-12-2025 Un Audited	31-12-2024 Un Audited	
I	Income					
	Revenue From Operations	3,557.80	5,220.13	936.07	7,135.95	12,028.66
	Other Income	20.25	2.72	1.89	12.62	16.85
	Total Income (I)	3,578.05	5,222.85	937.96	7,148.57	12,045.51
II	Expenses					
	Cost of materials consumed	2,610.24	4,082.98	538.91	4,338.57	7,128.82
	Changes in inventories of finished goods, Stock-in-Trade and work-	-603.10	-787.16	25.74	357.61	329.89
	Employee benefits expense	171.30	106.17	122.32	363.43	488.19
	Finance costs	157.83	86.61	88.66	280.10	371.52
	Depreciation and amortization expense	35.33	45.21	-	94.58	177.39
	Other expenses	145.12	444.36	191.44	574.39	860.88
	Total expenses (II)	2,516.72	3,978.17	967.07	6,008.68	9,356.69
III	Profit/(loss) before tax (I-II)	1,061.33	1,244.68	-29.11	1,139.89	2,688.82
IV	Tax expense					
	Current tax	527.73	315.85	323.09	710.01	757.20
	Deferred tax	18.40	-2.90	-1.13	-5.14	-17.46
	MAT Credit Entitlement	-	-	-102.50	48.01	-102.71
	Total Tax expense (IV)	546.13	312.95	219.46	752.88	637.03
V	Profit/(loss) after tax for the period (III-IV)	515.20	931.73	-248.57	387.01	2,051.79
VI	Other Comprehensive Income					
	Items that will not be reclassified to profit or loss	0.34	-	-	-	-
	Re-measurement gain I (loss) on defined benefit plans	-	-	-	-	-
	Items that will be reclassified to profit or loss	-	-	-	-	-
	Total Other Comprehensive Income (VI)	0.34	-	-	-	-
VII	Total Comprehensive Income for the period (V+VI)	515.54	931.73	-248.57	387.01	2,051.79
VIII	Earnings per equity share					
	Basic	1.13	2.22	-0.83	1.30	6.37
	Diluted	1.13	2.22	-0.83	1.30	6.37

Date: February 09, 2026

Place : Rajkot

SIGNED FOR IDENTIFICATION BY

R V D & Co.

Chartered Accountants

FRN 143936W

Date: 09/02/2026

Place: Rajkot

For and on behalf of Board of Directors,
Antlon Healthcare Limited (CIN: U24230GJ2013PLC077543)


Punitkumar R. Rassodia
Managing Director 6696258


Naveed A. Vaghani
Whole Time Director 6695083

Anlon Healthcare Limited

CIN: U24230GJ2013PLC077543

Notes to the Standalone Financial Result for the period ended on 31-12-2025

1 Corporate information

Anlon Healthcare Limited ("the Company") is a research-intensive manufacturing company engaged in the production of Active Pharmaceutical Ingredients (APIs) and drug intermediates. The Company is based in Rajkot, India, and has earned global recognition for manufacturing high-quality pharmaceutical bulk drugs that adhere to stringent international standards.

Anlon Healthcare Limited is a publicly listed company in India. The equity shares of the Company are listed on the National Stock Exchange of India Limited (NSE) under the symbol "AHCL" and on the BSE Limited (Bombay Stock Exchange) under the code 544497. The Company was listed on both exchanges on September 3, 2025.

2 Basis of Preparation

The Financial Statements of the Company have been prepared to comply with the Indian Accounting standards ("Ind AS"), including the Rules notified under the relevant provisions of the Companies Act, 2013, (as amended from time to time) and Presentation and disclosure requirements of Division II of Schedule III to the Companies Act, 2013, (Ind AS Compliant Schedule III) as amended from time to time. The Company follows indirect method prescribed in Ind AS 7 – Statement of Cash Flows for presentation of its cash flows.

The standalone financial statements have been prepared on a historical cost basis, except for certain financial assets and liabilities which have been measured at fair value (refer accounting policy regarding financial instruments) and derivative financial instruments.

The standalone financial statements are presented in Indian Rupees (₹) and all values are rounded to the nearest lakh (₹00,000), except when otherwise indicated. Further All assets and liabilities have been classified as current and non-current as per the Company's normal operating cycle and other criteria set out in the Schedule III of the Act and Ind AS 1 - Presentation of Financial Statements.

3 Segment Reporting

Anlon Healthcare Limited is primarily engaged in the business of manufacturing and sale of Active Pharmaceutical Ingredients (APIs). The entire operations of the Company are managed and reviewed by the management as one integrated business segment. Accordingly, based on the "management approach" prescribed under Ind AS 108 – Operating Segments, the Company has determined that segment reporting is not applicable to its operations.

4 The Status of investor complaints received by the company is as follows :

Number of Investor Complaints carried forward from the quarter ended 30.09.2025	1.00
Number of Investor Complaints received for the period 01.11.2025 – 31.12.2025	-
Number of Investor Complaints resolved during the quarter 01.11.2025-31.12.2025	1.00
Number of Investor Complaints lying unresolved for the quarter ended 31.12.2025	-

Type of Complaints: -

Share related	1.00
Dividend related	-
Annual reports related	-
MISC – Others /Application money/Refund/IPO	-

SIGNED FOR IDENTIFICATION BY
R V D & Co.
Chartered Accountants
FRN 143936W

Date 09/02/2026
Place : Rajkot

5 List of Group Companies or Subsidiary company
Nil

6 The above financial results of Anlon Healthcare Limited (the "Company") were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meetings held on [] and []5, respectively


7 The figures for the previous year have been re-grouped, re-classified, and re-arranged wherever necessary to conform to the current year's presentation and classification. Such re-grouping or re-arrangement has been carried out to facilitate a more appropriate comparison with the current year's financial statements.

8 Other Expenses includes operational, statutory, and administrative expenses Power Fuel,Packing Material,Factory Electricity Expenses,Freight Inward,Advertisement Expenses,Canteen and -Import Duty Expenses Etc

9 IPO-related expenses incurred by the Company, to the extent they represent incremental costs directly attributable to the issuance of equity shares, have been adjusted against Securities Premium in accordance with Ind AS 32. Other expenses, not directly attributable to the issue of equity instruments, have been recognised in the Statement of Profit and Loss.

For and on behalf of Board of Directors,
Anlon Healthcare Limited (CIN: U24230GJ2013PLC077543)


Punitkumar R. Rasadia
Managing Director 6696258



Place : Rajkot
Date : February 09,2026

SIGNED FOR IDENTIFICATION BY
R V D & Co.
Chartered Accountants
FRN 143936W

Date 09/02/2026
Place : Rajkot



To,
The Board of Directors
Anlon Healthcare Limited
101/102-Silver Coin Complex,
Opp. Crystal Mall, Kalawad Road,
Rajkot 360005, Gujarat (INDIA).

Sub: Statutory auditor's certificate in respect of regulation under Chapter IV Regulation 32 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended from time to time.

Dear Sir,


1. This certificate is issued in accordance with a request received from Anlon Healthcare Limited (the 'Company').
2. The Company was listed on National Stock Exchange of India Ltd & Bombay Stock Exchange on September 03, 2025. Pursuant to this initial public offer, the Company is required to submit a certificate with respect to utilization of the proceeds and indicate deviations, if any, from the objects stated in the offer document. Accordingly, We, R V D & Co., Chartered Accountants, the statutory auditors have been requested by the Company to verify the accompanying statement ('Annexure I') in respect of utilization of the funds for its intended purpose.
3. A copy of the accompanying statement has been attached.

Management's responsibility

4. The preparation of Annexure I is the responsibility of the management of the Company.
5. The preparation of the assertions for this certificate is the responsibility of the Management of the Company including the preparation and maintenance of all accounting and other relevant supporting records and documents. This responsibility includes the design, implementation and maintenance of internal control relevant to the preparation and presentation of the assertions for this certificate and applying an appropriate basis of preparation; and making estimates that are reasonable in the circumstances.

Our Responsibility

6. Our responsibility is to give a limited assurance as to whether there is any deviation in the utilization of the proceeds from the objects stated in the Prospectus dated August 30, 2025 filed with the Securities and Exchange Board of India ("Prospectus").
7. We have examined the Annexure I prepared by the Company on a test check basis and initialed it for identification purposes only.
8. We have conducted our verification and issued this certificate in accordance with the Guidance Note on Reports or Certificates for Special Purposes to the extent applicable (the "Guidance Note") issued by the Institute of Chartered Accountants of India. The Guidance Note requires that we comply with the ethical requirements of the Code of Ethics issued by the Institute of Chartered Accountants of India.
9. We have complied with the relevant applicable requirements of the Standard on Quality Control (SQC) 1, "Quality Control for Firms that Perform Audits and Reviews of Historical Financial Information, and other Assurance and Related Services Engagements" as revised from time to time.



"Level-6", Office No 604-605, Near AP Park, Opp Imperial Heights, Rajkot-360005

+91 6356 797 885

0281 - 2991685

office@cakda.in

www.cakda.in

10. We have performed the following procedures in relation to this certificate:

1. Obtained the Prospectus dated August 30,2025 filed with the Securities and Exchange Board of India
2. Reviewed Board and auditing committee meeting minutes relating to utilisation of IPO proceeds and unutilized IPO funds
3. Obtained the unaudited books of accounts for the quarter ended December 31, 2025
4. Obtained necessary records and documentation to verify Annexure I
5. Obtained necessary representations from the Management of the Company.


Conclusion

11 Based on the examination and procedures performed by us as stated above and according to the representation, information and explanation given to us by the management, we certify that the proceeds have been utilized for the intended purposes and there is no deviation in the utilization of the proceeds from the objects stated in the Prospectus dated August 30,2025 filed with the Securities and Exchange Board of India.

Restriction on use

(iii) The certificate has been issued at the request of the Company, for submission to the National Stock Exchange and Bombay Stock Exchange pursuant to the requirements of regulation under Chapter IV Regulation 32 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended from time to time. Accordingly, we do not accept or assume any liability or any duty of care for any other purpose or to any other person to whom this report is shown or into whose hands it may come without our prior consent in writing.

For, R V D & Co
Chartered Accountants
ICAI Firm Registration No 143936W


Kaushal V.Dave
(Partner)
Membership No 174550
UDIN: 26174550ADBFTO4160



Date: February 09th, 2026
Place: Rajkot

Annexure –I Statement of Deviation/Variation in utilisation of funds raised

Name of Listed Entity	Anlon Healthcare Limited
Mode of Fund Raising	Public Issue / Right Issue / Preferential Issue / QIP / Others
Date of Raising Funds	Issue Opened on: August 26, 2025 Issue Closed on: August 29, 2025
Amount Raised (In Rs.)	Rs.12,103.00 Lacs
Report filed for Quarter/ Half Year ended	December 31, 2025
Monitoring Agency	Yes
Monitoring Agency Name, if applicable	Crisil Ratings Limited
Is there a Deviation/Variation in use of funds raised	No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	Not Applicable
If Yes, Date of shareholder Approval	Not Applicable
Explanation for the Deviation/ Variation	Not Applicable
Comments of the Audit Committee after review	No Comment
Comments of the Auditors, if any	No Comment



Object(S)	Amount as per final offer document	Amount utilised at the beginning of the reported quarter	Amount utilised during the reported quarter	Amount utilised at the end of the reported quarter	Total unutilized amount as at the end of the reported quarter	Reason for idle funds	Proposed course of actions
Funding capital expenditure requirements for the expansion of our Manufacturing Facility	3,071.95	634.99	480.00	1,114.99	1,956.96		
Full or part repayment and/or pre-payment of certain outstanding secured borrowing (term loan) availed by our Company	500.00	500.00	-	500.00	-		
Funding the Working capital requirement	4,315.00	4,315.00		4,315.00	-		
Offer Expense	1,513.05	1,416.86	-	1,416.86	96.19		
General corporate purposes	2,703.00	1,378.60	853.59	2,232.86	470.81		
Total	12,103.00	8,245.45	1,333.59	9,579.04	2,523.96		

Note: During the quarter ended December 31, 2025, the Company transferred Rs 800.00 Lacs from its Monitoring Account to its various Current Accounts for utilization towards objects of the issue for operational ease.



February 09, 2026

PAN: CWCPM1726K

HITESH BAVANJIBHAI MAKWANA

BHIMA JETHA,
LUNIVAV,
RAJKOT - 360311,
GUJARAT

To,

Board of Directors,

ANLON HEALTHCARE LIMITED

101/102 - SILVERCOIN COMPLEX,
OPP. CRYSTAL MALL,
KALAWAD ROAD,
RAJKOT - 360005,
GUJARAT

Dear Sirs,

Re: Resignation from directorship of the company

With reference to the above, I, HITESH BAVANJIBHAI MAKWANA, wish to inform you that due to my pre-occupation, I am unable to continue as a Chief Financial Officer on the board of directors of the company. Therefore, I am tendering this resignation form Chief Financial Officer of the company w.e.f. February 09, 2026.

Kindly accept the same and complete necessary formalities.

Thanking you.



Hitesh Makwana

Place: Rajkot

Date: 09/02/2026

February 09, 2026

DIN: 00294480

SHAILESH KANTILAL THAKKAR
SHUBH, 1 SHREE RAM PARK,
NR. SIDDHNATH MAHADEV TEMPLE,
UNIVERSITY ROAD,
RAJKOT - 360005, GUJARAT

To,
Board of Directors,
ANLON HEALTHCARE LIMITED
101/102 - SILVERCOIN COMPLEX,
OPP. CRYSTAL MALL,
KALAWAD ROAD,
RAJKOT - 360005,
GUJARAT

Dear Sirs,


Re: Resignation from directorship of the company

With reference to the above, I, SHAILESH KANTILAL THAKKAR, wish to inform you that due to my pre-occupation and deteriorating health conditions, I am unable to continue as a director on the board of directors of the company. Therefore, I am tendering this resignation form directorship of the company w.e.f. February 09, 2026.

Other than the above, there are no material reasons for my resignation from the Company.

Kindly accept the same and complete necessary formalities.

Thanking you.



Shailesh Thakkar

Place: Rajkot

Date: 09/02/2026